Completed PHASE3 INTERVENTIONAL 2-arm NCT03591406

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

An Open-label, Randomised Controlled Multi-centre Study to Assess the Impact of Ferric Carboxymaltose in Correcting Iron Deficiency Anaemia Compared With Venofer® (Iron Sucrose) in Chinese Subjects

Sponsor: Tigermed Consulting Co., Ltd

Conditions Iron Deficiency Anemia

Interventions Ferric carboxymaltose Iron sucrose

Updated 8 times since 2018 Last updated: May 28, 2021 Started: Jul 3, 2017 Primary completion: Feb 25, 2019 Completion: Feb 25, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Iron Deficiency Anemia, this trial is completed. The trial is conducted by Tigermed Consulting Co., Ltd and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3
Jun 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

May 2020 — Jun 2020 [monthly]

Completed PHASE3
May 2019 — May 2020 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Aug 2018 — May 2019 [monthly]

Recruiting PHASE3

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tigermed Consulting Co., Ltd
Vifor (International) Inc.

Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China